Form 4: Akero Therapeutics COO Jonathan Young Reports Stock Option Exercise and Share Acquisition

Jonathan Young, COO of Akero Therapeutics, exercised stock options and acquired shares, increasing his total holdings.

Summary

• On March 1, 2024, Jonathan Young, the Chief Operating Officer of Akero Therapeutics, exercised stock options to acquire 83,321 shares of common stock at a price of $0.615 per share.
• Following this transaction, Young directly owns 268,957 shares of Akero Therapeutics common stock.
• Young also disclaims beneficial ownership of 60,000 shares held in irrevocable trusts for his children, for which his spouse is the trustee.
• The exercised options were vested and currently exercisable with an expiration date of October 17, 2028.
• The report also notes that 505 shares were acquired under the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan on June 30, 2023.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option exercise, which doesn't inherently indicate positive or negative sentiment about the company's performance.

Positives

• The exercise of stock options by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the actions of company executives.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a key executive.

Key Dates